Taiwan to boost biotech R&D and product lines
This article was originally published in Clinica
Executive Summary
Taiwan is to boost its biotechnology translational research with greater investment and infrastructure development. Taiwan's deputy health minister Dr Yen-jen Sung, made the commitment at the APEC Biotechnology Conference in Taipei last month, according to the Taipei Times. The move is to safeguard the region against the potential risks of global epidemics, such as the SARS outbreak in 2003. The first priority would be to attract more researchers and develop research infrastructure, said Mr Sung, followed by the promotion of tech transfer, and the commercialisation of newly-developed products. He said that the government would be financing research in the field.
You may also be interested in...
Asia Regulatory Forum Update
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia adopts interim device authorisation regulation
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
Canada takes action to increase more adverse event reporting
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.